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Abstract
Craniopharyngiomas (CPs) have had a prominent place in neurosurgery due to both the
technical difficulty and controversy regarding the optimal treatment of these benign
tumors. Harvey Cushing famously described craniopharyngiomas in 1936 as “the most
forbidding of the intracranial tumors.” Seventy years later, Rutka still wrote: “There is no
other primary brain tumor that evokes more passion, emotion, and as a result, contro-
versy than does the CP.” Craniopharyngiomas comprise 1–2% of all brain tumors and
occur in a bimodal distribution, with 40% of cases occurring between age 5–15 years and
60% occurring at ages >55 years. The differential diagnosis for craniopharyngioma can
include a variety of entities, including pituitary macroadenoma, metastasis, Rathke’s cleft
cyst, colloid cyst, glioma, meningioma, germinoma, abscess, sarcoid, or aneurysm. Imag-
ing characteristics usually include a solid cystic lesion, speckled with calcifications in 50–
80% of craniopharyngiomas (especially pediatric patients), as well a presentation with
hypopituitarism and diabetes insipidus, which influence clinical thinking toward
establishing this diagnosis.
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1. Clinical case vignette
A 42-year-old woman presented, as a transfer from an outside hospital, with increased forget-
fulness, fatigue, as well as intermittent double vision leading to accidents. In addition, she
complained of increased thirst and urination. She was concurrently taking lithium and loraz-
epam for psychiatric reasons. Imaging with CT revealed a large suprasellar mass extending
into the third ventricle (Figure 1). The patient had laboratory studies performed (Table 1) and
underwent a formal ophthalmology examination, which revealed red desaturation and a
depressed visual field consistent with compressive optic neuropathy.
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2. Overview
Craniopharyngiomas (CPs) have had a prominent place in neurosurgery due to both the
technical difficulty and controversy regarding the optimal treatment of these benign tumors.
Harvey Cushing famously described craniopharyngiomas in 1936 as “the most forbidding of
the intracranial tumors.” Seventy years later, Rutka still wrote: “There is no other primary
brain tumor that evokes more passion, emotion, and as a result, controversy than does the
CP” [1]. Craniopharyngiomas comprise 1–2% of all brain tumors and occur in a bimodal
distribution, with 40% of cases occurring between age 5–15 years and 60% occurring at ages
>55 years.
The differential diagnosis for craniopharyngioma can include a variety of entities, including
pituitary macroadenoma, metastasis, Rathke’s cleft cyst, colloid cyst, glioma, meningioma,
germinoma, abscess, sarcoid, or aneurysm. Imaging characteristics usually include a solid
cystic lesion, speckled with calcifications in 50–80% of craniopharyngiomas (especially pediat-
ric patients), as well a presentation with hypopituitarism and diabetes insipidus, which influ-
ence clinical thinking toward establishing this diagnosis.
Figure 1. A–C. 4.0  3.3  4.0 cm, suprasellar mass with cystic and solid components extending into the third ventricle.
No calcifications or hydrocephalus is seen.
Laboratory study Result
Urine specific gravity 1.020
Prolactin 13
Thyroid function tests TSH 0.17, T4 4.9, T3 71, Free T4 0.8
Luteinizing hormone < 0.1
Follicle stimulating hormone < 0.1
IGF-1 201
Table 1. Patient’s laboratory findings.
Brain Tumors - An Update204
3. Subtypes of craniopharyngioma
Craniopharyngiomas are benign lesions which arise from the neuroepithelium in the sellar
region. They are classically subdivided into two distinct entities based on both genetic and
morphologic differences. Adamantinomatous CP (aCP), primarily seen in childhood, occurs
more commonly than papillary CP (pCP), which is more often seen in adults [2]. In histologic
sections, adamantinomatous CP is poorly circumscribed, often multi-cystic and calcified, and
is associated with β-catenin and epidermal growth factor receptor (EGFR) overexpression.
Papillary CP, on the other hand, is well-circumscribed, less calcified, characterized by solid
components, and displays less adherence to surrounding structures [2]. Furthermore, pCP is
made up of fibrovascular stroma lined by well-differentiated squamous epithelium [2, 3].
In terms of histologic appearance, aCP usually shows nests and trabeculae of epithelium in
fibrocollagenous stroma, with peripheral cells showing nuclear palisading, loose central cells
termed “stellate reticulum,” and abundant keratin, cholesterol crystals, necrosis, and inflam-
mation. Papillary CP is well circumscribed, composed of the cores of fibrovascular stroma
lined by well-differentiated squamous epithelium that may separate to form pseudopapillae
which resembles squamous papilloma and without xanthogranulomatous inflammation. In
molecular staining of these tumors, the lack of expression of CK8 and CK20 keratin suggests a
craniopharyngioma, which differentiates them from Rathke’s cleft cyst or pituitary pars
intermedia. More recently, VE1 staining has also been utilized to identify BRAF mutations
which can help to differentiate between Rathke’s cleft cyst and craniopharyngioma [4].
4. Origin of craniopharyngioma
Craniopharyngiomas were long thought to arise as an embryonic malformation from the
anterior superior margin of the pituitary from residual Rathke’s pouch. Due to their embryonic
origin, they may even co-opt the blood supply of the wall and floor of the ventricle. More
modern studies have demonstrated that aCP can arise due to paracrine actives of β-Catenin
mutated cells, whereas pCP can arise via metaplastic transformation [2].
5. Clinical presentation
A triad of symptoms, involving visual impairment, neurological decline, and cognitive com-
promise, is generally seen in patients presenting with CP. The extent of morbidity associated
with CP is closely related to both the specific tumor location and its size. Hypothalamic disease
in patients can present as obesity (>50%), diabetes insipidus, thermoregulation disorder, som-
nolence, sleep apnea, and arrhythmia. Hypothalamic lesions, in particular, are associated with
increased rates of neurocognitive decline, and the importance of these neuropsychological
issues is evident in that fact that many of these patients continue to report cognitive issues at
follow-up, preventing return to previous performance at work or school. Clinically significant
hypopituitarism, usually involving several anterior pituitary hormones, occurs in the majority
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of patients presenting with CP. In nearly 90% of patients who are present with hypopituita-
rism in the long term, there is a significantly higher mortality risk related to both cardiovascu-
lar and cerebrovascular mortality, with an especially higher risk in females compared to males.
The evidence from multiple cohorts of patients suggests that the increased exposure to sex
hormones also manifests as cardiovascular risk greater in females compared to males [5].
6. Surgical treatment
Surgical resection of craniopharyngiomas is challenging due a number of different consider-
ations, primary of which is the importance of the surrounding neurovascular structures. Risks
of surgery include iatrogenic infarction, damage to the optic chiasm, cerebrospinal fluid (CSF)
leak, anosmia, CN III–VI palsies, seizures, and a relatively high rate of incomplete resections
and recurrences. Anatomic considerations play an especially important role when assessing
the appropriate surgical approach. The location of CP can be described in relation to the optic
chiasm, as either prechiasmatic (which displaces the chiasm posteriorly) or retrochiasmatic
(which displaces the chiasm anteriorly) [6]. While prior classification schemes designed for
transcranial surgery described CP in relation to the optic chiasm and the third ventricle,
Kassam et al. developed a novel classification based on the infundibulum which was used for
the expanded endoscopic approach. Craniopharyngiomas are grouped as pre-infundibular
(Type I), trans-infundibular (Type II), or post-infundibular (Type III) locations and occasionally
are located in the intraventricular region only (Type IV) [7]. Major variables that can also affect
the outcome in these patients include the tumor configuration, patient’s age, and medical
comorbidities, as well as the surgeon and center experience and availability of essential facili-
ties such as intra-operative imaging, ICU care, and multidisciplinary medical management
under endocrinology and radiation oncology.
The risk of recurrence is significant in patients with CP, especially if gross total resection (GTR)
is not achieved. Regardless of improved surgical techniques, post-mortem studies performed
by Bartlett et al. demonstrated tumor remnants that can remain attached to vital structures
such as the optic chiasm, hypothalamus, and/or critical vascular. These remnants can act as a
nidus for tumor growth post-surgery, leading to the relatively high rates of recurrence (about
33% within 36 months of surgery) observed in CP patients [8] (Figures 2 and 3).
Figure 2. (A) Type IV supra-infundibular craniopharyngioma with intraventricular extension and (B) post-operative MRI
demonstrates near-total resection of tumor with the opening of the lamina terminalis.
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7. Modern case series
Surgical resection can involve an open craniotomy or—alternatively—an endoscopic trans-
nasal approach. A series of open surgical resection employing the frontolateral approach for
extensive craniopharyngiomas greater than 4 cm in size reported by Gerganov et al. demon-
strated a gross total resection rate (GTR) of 87.5% by microscopic inspection and 62.5% when
based on post-operative MRI. Visual improvement was achieved in a significant number of
patients (37.5%) in this study. Side effects included new hormonal dysregulation (56.2%) and
new diabetes insipidus (75%) [9]. The rate of GTR resection in adults employing this approach
is comparable to rates achieved in pediatric patients and compares well with studies
employing various other open techniques [10–13]. A complex transpetrosal approach was
described by Al-Mefty et al. for CP located in the post-infundibular space [14].
A modern endoscopic series reported by Koutoursiou et al. of 47 adults and 17 children
demonstrated comparable GTR, near-total, subtotal, and partial resection rates of 37.5,
34.4, 21.9, and 6.5%, respectively. Major complications reported in this series included
CSF leak (23.4% initially and about 10% after the introduction of the modern endonasal
flap) and again recurrence rates of 34.4% [15]. An analysis of the reported endoscopic
series by Laws et al. found that endoscopic approaches for craniopharyngiomas are suit-
able especially if tumors are found to have a median intrasellar and subchiasmatic loca-
tion, with no parasellar solid component and no growth along the pituitary stalk [16].
However, tumors that extend to the optic chiasm and the third ventricle may also be
undertaken using the endoscopic approach if performed by experienced teams [17]. For
patients requiring re-operation due to recurrence, the endoscopic approach was also
shown to be effective, with no significant increase in the rates of complications according
to some authors [18]. The endoscopic transsphenoidal approach offers a number of advan-
tages including a surgical view in the axis of the tumor and the optic chiasm. Laws also
suggest that while resection of craniopharyngioma is commonly associated with hypopi-
tuitarism, the transsphenoidal approach may offer the advantage of the reduced risk of
permanent diabetes insipidus [19].
Figure 3. Recurrent cyst at 6 months follow-up. (A) Sagittal and coronal T1; (B) and (C) coronal T1 after transcortical
approach involving septostomy with fenestration of the lateral ventricles and third ventriculostomy.
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However, the endoscopic approach has certain disadvantages in that it is not well suited for
masses that are postchiasmatic or for lesions with prominent lateral extensions [16]. In situa-
tions of a recurrent craniopharyngioma after craniotomy, the trans-nasal approach may offer
the distinct advantage of a previously untouched approach to the lesion, and an endoscopy
enables the surgeon to assess the anatomy of the subchiasmatic and retrochiasmatic regions
more closely. If preservation or restoration of vision is the primary goal, this should be strongly
considered. Endoscopic approaches also offer the advantage of reducing morbidity associated
with brain retraction typically employed during transcranial approaches [16].
A comprehensive literature review performed by Komotar et al. claimed higher rates of GTR
with endoscopic surgery compared to open resection (66 vs. 48%), higher likelihood of visual
improvement (56 vs. 33%), although with a higher risk of CSF leak (18.4 vs. 2.6%). However, it
is important to note that the paper suffers from systematic methodological flaws and selection
bias since the mean follow-up time for the patients who underwent open resection in this
study was 65 months, as opposed to 25.1 months for the endoscopically treated group [20].
More recent series comparing the two approaches were not able to establish similar significant
differences in treatment outcomes.
In conclusion, the endoscopic approach may be most appropriate in certain patients who present
with intrasellar and Type I lesions, whereas an open resection, employing a frontotemporal
craniotomy, may be more suitable for intra-infundibular or post-infundibular lesions. In patients
presenting with cystic CP, stereotactic management is appropriate to aspirate the cystic compo-
nent of the mass before pursuing other avenues of treatment (e.g., radiation therapy).
8. Radiation therapy for craniopharyngioma
For much of the intervening decades since neurosurgery for CP was described, the debate
largely revolved about the optimal treatment strategy, whether aggressive surgical resection or
conservative surgery offered patients the best option. Among the two fundamental schools of
thought regarding the optimal approach to treat craniopharyngioma, one advocated for GTR
for all patients with radiation reserved for salvage therapy due to anticipated adverse effects of
radiation [21]. The alternative management suggested was that of a subtotal resection or
biopsy and cyst decompression in combination with adjuvant radiation therapy. Advantages
of this approach include lower morbidity and improved quality of life [22]. Although the
surgical goal remains maximal tumor resection with minimal morbidity, it is estimated that
33% of patients will present with some form of recurrence within the first few years. It is
especially clear that radiation therapy is a key element of treatment for these patients with
recurrent craniopharyngioma.
In a comprehensive review of a published series of CP patients, Yang et al. were able to demons-
trate that subtotal surgery in conjunction with post-operative radiation results in improved
survival in patients with CP [23]. This approach employing rather conservative surgery has the
advantage of reducing the risks of hypopituitarism and hypothalamic injury. The results from
various meta-analyses were corroborated and further expanded with evidence obtained from a
Brain Tumors - An Update208
large single-center series [24]. Conservative resection with adjuvant radiation was found to be a
superior strategy in treating patients. Schoenfeld et al. reported a cohort of patients in which
there was no significant difference between GTR and subtotal resection (STR) with radiation
therapy (XRT) in terms of overall survival or progression-free survival at 2 years [25], with less
endocrinological side effects observed in the STR group.
The key to progression-free survival appears to be conservative surgery with subsequent radia-
tion therapy. Radiation therapy can include various regimens employing conventional external
beam radiation therapy, stereotactic radiosurgery, or proton beam therapy. Although radiation
offers patients the possibility of treatment with reduced morbidity and mortality, side effects of
radiation include enlargement of a cystic tumor, fatigue, skin effects, increased intracranial
pressure, and transient or permanent optic neuropathy. Moreover, radiation may have long-
term effects such as hypopituitarism in 30–50% of patients, cranial nerve palsies, cerebrovascular
diseases, and secondary malignancies. Fortunately, radiation therapy offers excellent outcomes
with progressive-free survival between 5 and 10 years of 90% and 100%, respectively [26].
9. Future directions
As with many other cancers, targeted molecular therapies offer the promise of effective treat-
ment without the need for extensive surgery or radiation. Genetic studies of aCP and pCP
identified genetic characteristics of each subtype, that may eventually be targeted by specific
molecular therapies for CP. Genomic analysis of aCP revealed mutations in CTNNB1 (β-
catenin) in nearly all cases and BRAF mutations in most pCPs. These signaling pathways are
currently being interrogated for targeted molecular therapies. Inhibitors of the BRAF proto-
oncogene employing modern drugs such as Dabrafenib or Vemurafenib, or by prescribing
MEK inhibitors, such as Trametinib, are already being studied as therapies for pCP. Inhibition
of similar molecular pathways in melanoma, amelanoblastoma, hairy cell leukemia, and pleo-
morphic xanthoastrocytoma has already demonstrated the clinical promise of these therapies
[27, 28]. Multicenter phase-2 clinical trials at the National Cancer Institute are currently under-
way evaluating BRAF/MEK inhibition in the treatment of craniopharyngioma [27].
Regardless of the therapeutic strategies that are utilized, it is evident that craniopharyngiomas
continue to present a distinct oncologic challenge that still needs to be overcome. Quality of life
is a key consideration in this disease, and long-term follow up, involving a multidisciplinary
team, is a necessary element of care of these patients. The combination of minimally invasive
surgery and radiosurgery will, in the near future, result in a minimally morbid approach to
this disease to allow patients improved quality of life.
10. Conclusions
Since Cushing’s early writings, describing surgery for craniopharyngioma, our strategies to
treat this challenging disease have evolved with modern technology to include endoscopic and
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radiation therapy. The widespread availability and adoption of these techniques have led to
endoscopic treatment and radiation therapy becoming indispensable facets of treatment of
craniopharyngioma. As our molecular understanding of craniopharyngioma continues to
grow, there is considerable hope for the development of effective targeted therapies.
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